Literature DB >> 29959264

EEG findings in CAR T-cell therapy-related encephalopathy.

Aline Herlopian1, Jorg Dietrich2, Jeremy S Abramson2, Andrew J Cole2, Michael B Westover2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29959264      PMCID： PMC6093761          DOI： 10.1212/WNL.0000000000005910

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

1.  Generalized periodic discharges in the critically ill: a case-control study of 200 patients.

Authors:  Brandon Foreman; Jan Claassen; Karine Abou Khaled; Jeffrey Jirsch; Daniel M Alschuler; John Wittman; Ronald G Emerson; Lawrence J Hirsch
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

2.  Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.

Authors:  S Kuramitsu; M Ohno; F Ohka; S Shiina; A Yamamichi; A Kato; K Tanahashi; K Motomura; G Kondo; M Kurimoto; T Senga; T Wakabayashi; A Natsume
Journal:  Cancer Gene Ther       Date:  2015-10-09       Impact factor: 5.987

Review 3.  Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.

Authors:  Marcela V Maus; Bruce L Levine
Journal:  Oncologist       Date:  2016-03-23

Review 4.  New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.

Authors:  Frank Kroschinsky; Friedrich Stölzel; Simone von Bonin; Gernot Beutel; Matthias Kochanek; Michael Kiehl; Peter Schellongowski
Journal:  Crit Care       Date:  2017-04-14       Impact factor: 9.097

5.  Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.

Authors:  Pavel Otáhal; Dana Průková; Vlastimil Král; Milan Fabry; Petra Vočková; Lucie Latečková; Marek Trněný; Pavel Klener
Journal:  Oncoimmunology       Date:  2015-12-03       Impact factor: 8.110
  5 in total
  11 in total

1.  Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.

Authors:  Paolo Strati; Loretta J Nastoupil; Jason Westin; Luis E Fayad; Sairah Ahmed; Nathan H Fowler; Fredrick B Hagemeister; Hun J Lee; Swaminathan P Iyer; Ranjit Nair; Simrit Parmar; Maria A Rodriguez; Felipe Samaniego; Raphael E Steiner; Michael Wang; Chelsea C Pinnix; Sherry Adkins; Catherine M Claussen; Charles S Martinez; Misha C Hawkins; Nicole A Johnson; Prachee Singh; Haleigh E Mistry; Sandra Horowitz; Shirley George; Lei Feng; Partow Kebriaei; Elizabeth J Shpall; Sattva S Neelapu; Sudhakar Tummala; T Linda Chi
Journal:  Blood Adv       Date:  2020-08-25

Review 2.  Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity.

Authors:  Luis Nicolas Gonzalez Castro; Jorg Dietrich
Journal:  Neurooncol Pract       Date:  2020-11-29

3.  Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy.

Authors:  Rosyli Reveron-Thornton; Brian J Scott; David Post; Anna Finley Caulfield; Katherine Werbaneth; Dominic A Hovsepian; Jay Spiegel; David Miklos; Reena P Thomas; Chirag B Patel
Journal:  Neurohospitalist       Date:  2021-03-11

4.  EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity.

Authors:  Juliane Gust; Colleen E Annesley; Rebecca A Gardner; Xiuhua Bozarth
Journal:  J Clin Neurophysiol       Date:  2021-03-01       Impact factor: 2.590

Review 5.  In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy.

Authors:  Jorge Garcia Borrega; Philipp Gödel; Maria Adele Rüger; Özgür A Onur; Alexander Shimabukuro-Vornhagen; Matthias Kochanek; Boris Böll
Journal:  Hemasphere       Date:  2019-03-29

Review 6.  Cytokines in CAR T Cell-Associated Neurotoxicity.

Authors:  Juliane Gust; Rafael Ponce; W Conrad Liles; Gwenn A Garden; Cameron J Turtle
Journal:  Front Immunol       Date:  2020-12-16       Impact factor: 7.561

7.  Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity.

Authors:  Elisaveta Sokolov; Philipp Karschnia; Reuben Benjamin; Robert D M Hadden; Robert C D Elwes; Lee Drummond; Devyani Amin; Vitor Paiva; Alex Pennisi; Aline Herlopian; Matthew Frigault; Robin Sanderson; Shafqat Inam; Andrew J Cole; Jorg Dietrich
Journal:  BMJ Neurol Open       Date:  2020-06-18

8.  Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy.

Authors:  Umberto Pensato; Lorenzo Muccioli; Ilaria Cani; Damir Janigro; Pier Luigi Zinzani; Maria Guarino; Pietro Cortelli; Francesca Bisulli
Journal:  Ann Clin Transl Neurol       Date:  2021-03-29       Impact factor: 4.511

9.  Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapy.

Authors:  Lila D Faulhaber; Anthea Q Phuong; Kendra Jae Hartsuyker; Yeheun Cho; Katie K Mand; Stuart D Harper; Aaron K Olson; Gwenn A Garden; Andy Y Shih; Juliane Gust
Journal:  Brain Commun       Date:  2021-12-31

10.  EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations.

Authors:  Isabelle Beuchat; Husain H Danish; Daniel B Rubin; Caron Jacobson; Matthew Robertson; Henrikas Vaitkevicius; Jong Woo Lee
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 13.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.